Buchumschlag

Celebrating Ulrik Ringborg: multi-omics-based patient stratification for precision cancer treatment

Precision oncology is becoming a mainstay in the standard of care for cancer patients. Recent technological advancements have significantly lowered the cost of various tumor profiling approaches, broadening the reach of molecular diagnostics and improving patient access to precision oncology. In par...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Teleanu, Maria-Veronica (VerfasserIn) , Schneider, Annika R. P. (VerfasserIn) , Ball, Claudia R. (VerfasserIn) , Leber, Mathias Felix (VerfasserIn) , Stange, Christoph (VerfasserIn) , Krieghoff-Henning, Eva (VerfasserIn) , Beck, Katja (VerfasserIn) , Heilig, Christoph E. (VerfasserIn) , Kreutzfeldt, Simon (VerfasserIn) , Küster, Bernhard (VerfasserIn) , Lipka, Daniel (VerfasserIn) , Fröhling, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 10 May 2025
In: Biomolecules
Year: 2025, Jahrgang: 15, Heft: 5, Pages: 1-18
ISSN:2218-273X
DOI:10.3390/biom15050693
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/biom15050693
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2218-273X/15/5/693
Volltext
Verfasserangaben:Maria-Veronica Teleanu, Annika Schneider, Claudia R. Ball, Mathias Felix Leber, Christoph Stange, Eva Krieghoff-Henning, Katja Beck, Christoph E. Heilig, Simon Kreutzfeldt, Bernhard Kuster, Daniel B. Lipka and Stefan Fröhling
Beschreibung
Zusammenfassung:Precision oncology is becoming a mainstay in the standard of care for cancer patients. Recent technological advancements have significantly lowered the cost of various tumor profiling approaches, broadening the reach of molecular diagnostics and improving patient access to precision oncology. In parallel, drug development and discovery pipelines continue to evolve, driving targeted therapeutic options forward. Yet, not all patients harboring actionable molecular alterations respond to these interventions, and existing therapies do not cover the entire spectrum of potential molecular targets. In this review, we examine the current suite of omics technologies employed in clinical settings and underscore their roles in deepening our understanding of tumor biology and optimizing patient stratification for targeted treatments. We also highlight relevant precision oncology trials and share our own experiences using multi-omics data within a molecular tumor board framework. Finally, we discuss areas for future exploration aimed at propelling precision oncology to new heights.
Beschreibung:Gesehen am 20.10.2025
Beschreibung:Online Resource
ISSN:2218-273X
DOI:10.3390/biom15050693

Ähnliche Einträge